Company Overview of Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc., a biopharmaceutical company, develops treatments to optimize therapeutic benefits and reduce adverse effects for chronic and life-threatening diseases. The company offers ITCA 650 for the treatment of type 2 diabetes by using its subcutaneous delivery system (its technology platform), which is a matchstick-sized device, including a cylindrical titanium alloy reservoir that is inserted under the skin to allow the water from the extracellular fluid to enter the device at one end by diffusing through a semi-permeable membrane directly into a salt osmotic engine that expands to drive a piston at a controlled rate of travel, and forces the drug formulation to be relea...
155 Seaport Boulevard
Boston, MA 02210
Founded in 1995
Key Executives for Intarcia Therapeutics, Inc.
Executive Chairman, Chief Executive Officer and President
Chief Financial Officer and Vice President of Finance & Operations
Chief Legal Officer, Vice President and General Counsel
Chief Business Officer and Head of Corporate Development
Compensation as of Fiscal Year 2014.
Intarcia Therapeutics, Inc. Key Developments
Intarcia Therapeutics, Inc. Names Emad Rizk to Board of Directors
May 19 15
Intarcia Therapeutics, Inc. announced the appointment of Emad Rizk, MD, to its board of directors. Dr. Rizk is a well-respected leader in the healthcare industry, and an expert on payers and healthcare economics. He joins the company board as the company nears completion of its clinical development for ITCA 650 (a once- or twice-yearly continuous subcutaneous delivery of exenatide), its lead therapeutic candidate for the treatment of type 2 diabetes. Dr. Rizk currently serves as President and Chief Executive Officer of Accretive Health. He previously served as President of McKesson Health Solutions. Dr. Rizk was formerly a member of the board of DMAA: Care Continuum Alliance and currently serves on the boards of directors of the National Association for Hispanic Health, Manage Care Editorial, Accuray Inc. and Accretive Health.
Intarcia Therapeutics, Inc. Appoints Michael Williams as Chief Operating Officer
May 4 15
Intarcia Therapeutics, Inc. announced the appointment of Michael Williams into the newly created role of Chief Operating Officer (COO). Mr. Williams is a senior pharmaceutical executive with experience most recently at Takeda Pharmaceuticals, but also long and distinguished service at Pfizer and Bristol Myers Squibb. Mr. Williams will report directly to Kurt Graves, Intarcia's Chairman, President and CEO, and will be a member of the Leadership Team. He will have full accountability, in cooperation with the Executive Team, for building out the commercial capabilities and operational plans for ITCA 650, Intarcia's late-stage development candidate for the treatment of type 2 diabetes. Prior to joining Intarcia, Mr. Williams was Head of Global Marketing for Takeda Pharmaceuticals where he was responsible for establishing Takeda's first Global Marketing organization that included Global Market Access, Customer Insights and Global Brand Management.
Intarcia Therapeutics, Inc. Appoints James P. Brady as Vice President, Human Resources
May 1 15
Intarcia Therapeutics, Inc. announced the appointment of James P. Brady as Vice President, Human Resources, reporting directly to Kurt Graves, Intarcia's Chairman, President and CEO. As a new key member of the senior leadership team, Mr. Brady will work closely with the CEO and Leadership Team to assure the Company advances its business, brings in and retains top talent, and further embeds its core values and its dynamic culture. Another essential goal for Mr. Brady is to design, implement and evaluate programs to attract, retain, reward, and motivate top talent and top performance. Mr. Brady has more than 15 years of professional leadership experience educating top talent and building more aligned organizations. He most recently worked at Genzyme Corporation for almost a decade, half before and half after the Sanofi acquisition.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 27, 2015